Burning Rock Biotech (BNR) EBIT Margin (2019 - 2026)

Burning Rock Biotech's EBIT Margin history runs 8 years deep, the most recent figure standing at 17.45% for Q1 2026.

• In Q1 2026, EBIT Margin fell 604.0% year-over-year to 17.45%; the TTM figure through Mar 2026 stood at 11.41% (up 3560.0% YoY), while the FY2025 annual figure was 10.02%, up 5930.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 17.45%, down from 9.53% in the prior quarter.
• The five-year high for EBIT Margin was 7.74% in Q2 2025, with the low at 202.9% in Q2 2022.
• The 5-year median for EBIT Margin is 92.79% (2023), against an average of 90.57%.
• The sharpest annual moves came in 2022 and 2024: EBIT Margin slumped 4417 bps in 2022, then surged 11016 bps in 2024.
• Burning Rock Biotech's EBIT Margin stood at 152.88% in 2022, then increased by 10 bps to 137.37% in 2023, then jumped by 53 bps to 65.01% in 2024, then jumped by 85 bps to 9.53% in 2025, then slumped by 83 bps to 17.45% in 2026.
• Business Quant data shows BNR's EBIT Margin at 17.45% in Q1 2026, 9.53% in Q4 2025, and 12.26% in Q3 2025.